Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AGM votes at HSBC, Glencore and AstraZeneca on climate change, pay may face strong opposition
12:36pm, Thursday, 21'st Apr 2022
Several FTSE 100 companies will hold annual shareholder meetings in the coming week, with potentially contentious votes on climate issues and pay, including at Glencore PLC (LSE:GLEN), HSBC Holdings
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
09:47am, Wednesday, 20'th Apr 2022
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).
AstraZeneca a 'buy' for Deutsche Bank after lung cancer drug granted priority review
06:31am, Wednesday, 20'th Apr 2022
AstraZeneca PLC (LSE:AZN) (AstraZeneca PLC (LSE:AZN)) was labelled a ‘buy' by Deutsche Bank following this morning's announcement of a date for the US review of Enhertu, a new treatment for a rare t
AstraZeneca cancer drug receives priority FDA review as data points to its potential in lung cancer
03:49am, Tuesday, 19'th Apr 2022
AstraZeneca PLC (LSE:AZN) said its drug Enhertu has been granted a priority review by US regulators following the release of data underlining its potential in a group of lung cancer patients that curr
Will These Pharma Giants Pop or Flop on Clinical Study Readouts?
03:05pm, Tuesday, 12'th Apr 2022
Do results from an important clinical trial affect the stock price of pharma companies? We're about to find out, as several readouts are expected in the second quarter.
The Zacks Analyst Blog Highlights Costco Wholesale, AstraZeneca, Medtronic, Sony Group, and Applied Materials
04:09pm, Monday, 11'th Apr 2022 Zacks Investment Research
Costco Wholesale, AstraZeneca, Medtronic, Sony Group, and Applied Materials are part of top Analyst Blog.
3 Safe Stocks to Buy in an Uncertain Market
11:31am, Saturday, 09'th Apr 2022 The Motley Fool
Their solid underlying businesses and dividends make these stocks more secure than most.
3 Safe Stocks to Buy in an Uncertain Market
07:31am, Saturday, 09'th Apr 2022
Their solid underlying businesses and dividends make these stocks more secure than most.
Top Stock Reports for Costco, AstraZeneca & Medtronic
06:14pm, Friday, 08'th Apr 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), AstraZeneca PLC (AZN), and Medtronic plc (MDT).
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
05:02pm, Friday, 08'th Apr 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S
3 Things About Pfizer That Smart Investors Know
03:07pm, Friday, 08'th Apr 2022 The Motley Fool
The next few years might get a little bumpy.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
01:31pm, Friday, 08'th Apr 2022 Zacks Investment Research
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
Antibody Treatments for COVD-19 Face Challenges in the U.S.
10:32am, Friday, 08'th Apr 2022
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
7 Desirable Dividend Growth Stocks for Income Investors
07:06am, Friday, 08'th Apr 2022
Dividend growth stocks that are worth considering for the long-term for income investors. Low-beta stocks at an attractive valuation.
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
12:24pm, Thursday, 07'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AstraZeneca In-Licenses Preclinical Bispecific Antibody Candidate From Harbour BioMed For Up To $350M
